Study of TJ011133 in Participants With Relapsed/Refractory Advanced Solid Tumors and Lymphoma

NCT03934814 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

98

Enrollment

INDUSTRY

Sponsor class

Conditions

Solid Tumor
Lymphoma

Interventions

DRUG: TJ011133
DRUG: Pembrolizumab
DRUG: Rituximab

Sponsor

I-Mab Biopharma US Limited

Collaborators

[object Object]